CCND1 and neoplasm: Targeting these dysregulated cell cycle pathways holds promise for cancer therapies, such as restoring normal cell cycle checkpoints or inhibiting key regulatory proteins such as cyclin D1, which could potentially halt tumor growth and reduce cancer progression [38,39].